BR112018006866A2 - compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos - Google Patents

compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos

Info

Publication number
BR112018006866A2
BR112018006866A2 BR112018006866-7A BR112018006866A BR112018006866A2 BR 112018006866 A2 BR112018006866 A2 BR 112018006866A2 BR 112018006866 A BR112018006866 A BR 112018006866A BR 112018006866 A2 BR112018006866 A2 BR 112018006866A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
agonist compounds
ppar agonist
diseases
Prior art date
Application number
BR112018006866-7A
Other languages
English (en)
Other versions
BR112018006866B1 (pt
Inventor
Downes Michael
M. Evans Ronald
Kluge Arthur
Lagu Bharat
Miura Masanori
Kumar Panigrahi Sunil
Patane Michael
Samajdar Susanta
Senaiar Ramesh
Takahashi Taisuke
Original Assignee
Mitobridge, Inc.
The Salk Institute For Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018006866(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitobridge, Inc., The Salk Institute For Biological Studies filed Critical Mitobridge, Inc.
Publication of BR112018006866A2 publication Critical patent/BR112018006866A2/pt
Publication of BR112018006866B1 publication Critical patent/BR112018006866B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a compostos e composições úteis para aumentar a atividade de ppar. os compostos e composições aqui providos são úteis para o tratamento de doenças relacionadas ao ppar (p. ex., doenças musculares, doenças vasculares, doença desmielinizantes e doenças metabólicas).
BR112018006866-7A 2015-10-07 2016-10-05 Compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos BR112018006866B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US62/238,629 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US62/243,263 2015-10-19
US201662352348P 2016-06-20 2016-06-20
US62/352,348 2016-06-20
PCT/US2016/055521 WO2017062468A1 (en) 2015-10-07 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112018006866A2 true BR112018006866A2 (pt) 2018-10-16
BR112018006866B1 BR112018006866B1 (pt) 2023-11-21

Family

ID=57200096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006866-7A BR112018006866B1 (pt) 2015-10-07 2016-10-05 Compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos

Country Status (25)

Country Link
US (5) US10399958B2 (pt)
EP (3) EP3795566B1 (pt)
JP (2) JP6657413B2 (pt)
CN (3) CN113024467A (pt)
AU (3) AU2016333963C1 (pt)
BR (1) BR112018006866B1 (pt)
CA (1) CA3000431A1 (pt)
CO (1) CO2018004473A2 (pt)
DK (1) DK3359528T3 (pt)
EA (1) EA037371B1 (pt)
ES (2) ES2906379T3 (pt)
HK (1) HK1257907A1 (pt)
HU (1) HUE058154T2 (pt)
IL (3) IL258225B (pt)
JO (3) JO3738B1 (pt)
MA (2) MA52648A (pt)
MX (2) MX2020011099A (pt)
PH (1) PH12018500762A1 (pt)
PL (1) PL3359528T3 (pt)
PT (1) PT3359528T (pt)
SG (1) SG10201906400SA (pt)
TW (3) TWI730006B (pt)
UA (1) UA122237C2 (pt)
WO (1) WO2017062468A1 (pt)
ZA (4) ZA201802029B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058154T2 (hu) 2015-10-07 2022-07-28 Mitobridge Inc PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra
RU2746602C2 (ru) 2016-04-13 2021-04-16 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
CA3036723A1 (en) * 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
US20220331267A1 (en) * 2019-09-05 2022-10-20 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3221429A1 (en) 2021-06-02 2022-12-08 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
OA12362A (en) 2000-08-17 2004-04-07 Pfizer Substituted imidazoles as tafia inhibitors.
NZ538031A (en) * 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
RU2007112688A (ru) 2004-09-06 2008-10-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia
JP2008530154A (ja) 2005-02-15 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒアクチベーターとしてのアミド誘導体
GT200600407A (es) * 2005-09-07 2007-04-10 Compuestos ppar activos
BRPI0707338A2 (pt) 2006-01-30 2011-05-03 Transtech Pharma Inc derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase
KR20080098548A (ko) 2006-03-28 2008-11-10 노파르티스 아게 Ｇ 단백질 관련 질환의 치료를 위한 아미드 유도체 및 그의투여
PL2014652T3 (pl) 2006-04-18 2015-02-27 Nippon Chemiphar Co Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP2010520873A (ja) 2007-03-07 2010-06-17 ドン・ア・ファーム・カンパニー・リミテッド ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
EP2234622A4 (en) 2007-12-28 2011-03-09 Salk Inst For Biological Studi METHOD FOR INCREASING MUSCLE PERFORMANCE AND MUSCLE TONUS
EP2890313B1 (en) 2012-08-28 2016-09-21 KOC Universitesi Bone plate
WO2014165827A1 (en) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HUE058154T2 (hu) 2015-10-07 2022-07-28 Mitobridge Inc PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra
RU2746602C2 (ru) 2016-04-13 2021-04-16 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
CA3036723A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury

Also Published As

Publication number Publication date
CN108349904B (zh) 2021-08-31
JP6657413B2 (ja) 2020-03-04
IL275392B (en) 2022-05-01
TWI730408B (zh) 2021-06-11
KR20180095797A (ko) 2018-08-28
US11578052B2 (en) 2023-02-14
UA122237C2 (uk) 2020-10-12
US20200157074A1 (en) 2020-05-21
AU2019283837B2 (en) 2020-12-24
MX2020011099A (es) 2022-05-23
CN108349904A (zh) 2018-07-31
AU2016333963C1 (en) 2021-05-27
JP2020075939A (ja) 2020-05-21
TWI742479B (zh) 2021-10-11
IL275392A (en) 2020-07-30
EA037371B1 (ru) 2021-03-19
IL258225A (en) 2018-05-31
ZA202003664B (en) 2022-08-31
JOP20200230A1 (ar) 2022-10-30
AU2020281069A1 (en) 2021-01-07
PH12018500762A1 (en) 2018-10-29
TW201722919A (zh) 2017-07-01
US10906885B2 (en) 2021-02-02
AU2020281069B2 (en) 2022-10-27
ES2949852T3 (es) 2023-10-03
CO2018004473A2 (es) 2018-09-20
CN113024467A (zh) 2021-06-25
US20190337920A1 (en) 2019-11-07
HK1257907A1 (zh) 2019-11-01
HUE058154T2 (hu) 2022-07-28
ZA202003663B (en) 2022-08-31
EP3795566B1 (en) 2023-04-19
US20190084958A1 (en) 2019-03-21
EP3795566A1 (en) 2021-03-24
JP2018534355A (ja) 2018-11-22
ES2906379T3 (es) 2022-04-18
MA52648A (fr) 2021-10-13
TWI730006B (zh) 2021-06-11
EP3770146A1 (en) 2021-01-27
EA201890776A1 (ru) 2018-09-28
CA3000431A1 (en) 2017-04-13
BR112018006866B1 (pt) 2023-11-21
WO2017062468A1 (en) 2017-04-13
TW202012375A (zh) 2020-04-01
PL3359528T3 (pl) 2022-05-30
SG10201906400SA (en) 2019-08-27
US10479775B1 (en) 2019-11-19
MX2020011100A (es) 2022-05-23
JO3738B1 (ar) 2021-01-31
EP3359528A1 (en) 2018-08-15
WO2017062468A8 (en) 2017-05-11
IL258225B (en) 2021-08-31
EP3359528B1 (en) 2022-01-12
AU2016333963B2 (en) 2021-01-07
ZA202003662B (en) 2022-08-31
TW201943705A (zh) 2019-11-16
MA52098A (fr) 2021-01-27
DK3359528T3 (en) 2022-03-07
IL275387B (en) 2021-08-31
US10399958B2 (en) 2019-09-03
CN113004205A (zh) 2021-06-22
AU2019283837A1 (en) 2020-01-16
US20230373948A1 (en) 2023-11-23
IL275387A (en) 2020-07-30
US20210253549A1 (en) 2021-08-19
JOP20200231A1 (ar) 2022-10-30
ZA201802029B (en) 2022-01-26
KR20210126150A (ko) 2021-10-19
JP6866514B2 (ja) 2021-04-28
PT3359528T (pt) 2022-04-07
AU2016333963A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EA201691582A1 (ru) Новые фармацевтические препараты
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112016022785A2 (pt) composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112016030730A8 (pt) composto
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023015335-9 PROTOCOLO 870230066930 EM 31/07/2023 12:15.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2016, OBSERVADAS AS CONDICOES LEGAIS